INSULIN DETEMIR (Levemir®)

Clinical Indication

Comments

Patients should not be initiated on any Levemir® product as it is being discontinued. Any requests for new initiations should be referred to the clinician making the request.

Prescriptions for stable patients should continue unchanged at this time

National clinical guidance was published 14th August 2025; it is being reviewed by local specialists. A plan for managing LLR patients will be issued once agreed. Stock is expected to last until the end of 2026.

Date of classification

September 2025

Green

Medicines which could be started in any health care setting and do not require oversight by a specialist and which primary care would have full responsibility for prescribing and monitoring.